门冬氨酸钾镁联合胺碘酮治疗急性心肌梗死室性心律失常临床研究

Clinical Study of Potassium Magnessium Aspartape Combined with Amiodarone in Treating Ventricular Arrhythmias in Acute Myocardial Infarction

目的分析胺碘酮联合门冬氨酸钾镁治疗急性心肌梗死室性心律失常的临床疗效。方法选择医院2010年2月至2016年4月收治的急性心肌梗死室性心律失常患者150例,随机分为对照组和观察组,各75例。对照组患者单纯给予胺碘酮治疗,观察组给予门冬氨酸钾镁联合胺碘酮治疗,比较两组的临床疗效、心电图指标、实验室指标及不良反应。结果观察组总有效率和不良反应发生率分别为93.33%和6.67%,与对照组的81.33%和21.33%比较有显著性差异(P<0.05);两组治疗后十二导联心电图指标及实验室指标比较均有显著性差异(P<0.05)。结论胺碘酮联合门冬氨酸钾镁治疗急性心肌梗死室性心律失常疗效显著,不良反应相对更少,值得临床推广。

Objective To analyze the clinical effect of Potassium Magnessium Aspartape combined with Amiodarone in treating ventricu- lar arrhythmias in acute myocardial infarction. Methods Tota｜ly 150 patients with ventricular arrhythmias and acute myocardial infarc- tion from February 2010 to April 2016 were randomly divided into two groups,75 cases in each group. The control group was given Amiodarone, while the observation group was given Potassium Magnessium Aspartape combined with Amiodarone. The clinical efficacy, ECG,laboratory parameters and adverse reactions were compared between the two groups. Results The total effective rate and the inci- dence rate of adverse reactions in the observation group were 93.33% and 6.67% , which had significantly difference with 81.33% and 21.33% in the control group （P 〈 0.05）. After treatment,the twelve lead ECG and laboratory indexes of the two groups had sig- nificant differences （P 〈 0. 05）. Conclusion Potassium Magnessium Aspartape combined with Amiodarone in treating ventricular ar- rhythmias in acute myocardial infarction has significant effect with less adverse reactions,it is worthy of clinical promotion.